Dyadic and Scripps Partner on Rapid Hantavirus Antibody, Vaccine Development Using C1 Platform
DYAI•Dyadic Applied BioSolutions is partnering with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, leveraging its C1 microbial platform’s rapid development and scalable manufacturing capabilities. The collaboration builds on Dyadic’s prior Andes virus antibody work and ongoing programs funded by the Gates Foundation and CEPI.
1. Collaboration Scope
Dyadic Applied BioSolutions is collaborating with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including the Andes virus strain associated with HPS. The joint effort aims to leverage combined expertise in structure-based antigen design and rapid biologic production to accelerate preclinical development timelines.
2. C1 Platform Capabilities
Dyadic’s proprietary C1 microbial fermentation platform offers high-productivity, scalable biologic manufacturing and has demonstrated antibody neutralization performance comparable to mammalian systems in preclinical assays. Prior work includes development of a recombinant anti-Andes virus antibody rANDV-44 with pseudovirus neutralization activity matching ExpiCHO-produced material.
3. Strategic Partnerships and Funding
The collaboration builds on existing funded programs supported by the Gates Foundation, CEPI, and EU initiatives focused on pandemic preparedness. Dyadic plans to explore additional non-dilutive funding and external partnerships to expand antibody and vaccine candidate pipelines without diluting equity.
